Emrelis

Active Ingredient(s): Telisotuzumab Vedotin-tllv
FDA Approved: * May 14, 2025
Pharm Company: * ABBVIE INC
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Telisotuzumab Vedotin 20 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 0074-1044
Labeler:
Abbvie Inc.
Telisotuzumab Vedotin 100 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 0074-1055
Labeler:
Abbvie Inc.